Lisa Walter
Stock Analyst at RBC Capital
(4.14)
# 469
Out of 5,149 analysts
14
Total ratings
58.33%
Success rate
19.8%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Lisa Walter
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VRDN Viridian Therapeutics | Maintains: Outperform | $45 → $42 | $29.32 | +43.25% | 3 | Feb 27, 2026 | |
| UTHR United Therapeutics | Maintains: Outperform | $587 → $643 | $498.65 | +28.95% | 3 | Feb 26, 2026 | |
| APLS Apellis Pharmaceuticals | Maintains: Sector Perform | $22 → $21 | $20.16 | +4.17% | 2 | Feb 25, 2026 | |
| RYTM Rhythm Pharmaceuticals | Initiates: Outperform | $145 | $89.56 | +61.90% | 1 | Feb 19, 2026 | |
| MGTX MeiraGTx Holdings | Maintains: Outperform | $12 → $16 | $7.43 | +115.34% | 1 | Nov 14, 2025 | |
| FDMT 4D Molecular Therapeutics | Maintains: Outperform | $26 → $32 | $8.46 | +278.25% | 2 | Nov 11, 2025 | |
| EYPT EyePoint | Maintains: Outperform | $28 → $39 | $18.32 | +112.88% | 2 | Nov 6, 2025 |
Viridian Therapeutics
Feb 27, 2026
Maintains: Outperform
Price Target: $45 → $42
Current: $29.32
Upside: +43.25%
United Therapeutics
Feb 26, 2026
Maintains: Outperform
Price Target: $587 → $643
Current: $498.65
Upside: +28.95%
Apellis Pharmaceuticals
Feb 25, 2026
Maintains: Sector Perform
Price Target: $22 → $21
Current: $20.16
Upside: +4.17%
Rhythm Pharmaceuticals
Feb 19, 2026
Initiates: Outperform
Price Target: $145
Current: $89.56
Upside: +61.90%
MeiraGTx Holdings
Nov 14, 2025
Maintains: Outperform
Price Target: $12 → $16
Current: $7.43
Upside: +115.34%
4D Molecular Therapeutics
Nov 11, 2025
Maintains: Outperform
Price Target: $26 → $32
Current: $8.46
Upside: +278.25%
EyePoint
Nov 6, 2025
Maintains: Outperform
Price Target: $28 → $39
Current: $18.32
Upside: +112.88%